FDA Approves Merck ’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news